Since there are no cures for knee osteoarthritis (OA), exercise and weight loss remain the best first-line therapies to decrease pain and improve function, said Stephen P. Messier, PhD, professor and director of the J.B. Snow Biomechanics Laboratory at Wake Forest University.
Since there are no cures for knee osteoarthritis (OA), exercise and weight loss remain the best first-line therapies to decrease pain and improve function, said Stephen P. Messier, PhD, professor and director of the J.B. Snow Biomechanics Laboratory at Wake Forest University.
Transcript
What are the long-term impacts, individually and on the overall health system, if patients don't do things like exercise when they have knee osteoarthritis?
Right now, there are, as you well know, right now there are no cures for osteoarthritis. The best treatment is exercise and weight loss. We can get over 50% decline or reduction in pain and improvement in function along with a decrease in joint loads, decrease in inflammation, it goes on and on and on how good it is. Not to mention that it also affects other things, like type 2 diabetes, hypertension, self-efficacy, and so the nonpharmacologic interventions, right now, should be the first line of treatment for people with knee osteoarthritis.
And if they don’t do that, if they don’t do anything what you see is a decline in function, an increase in pain, more sedentary lifestyle, an increase in weight, decrease in self-efficacy, and so it can spiral downward pretty quickly. And so, it’s amazing the participants we had in our trials have been sedentary for their entire lives and all of a sudden now, we’re making athletes out of them. And not the kind of athlete that we think about, as most people think about, but for them to get out there and walk 3 days a week or strength train, loss a little bit of weight—they’re athletes. In fact, it’s probably more important for them because they’re doing this for their life, to maintain, to improve their life.
You know, we’re going to live a long time, and the last third of your life should be fun. You should be able to play with your grandchildren, and not have to sit on the couch and watch them play, and those kinds of things. What we find is, we’ve got 65-year-olds that are role models for the grandchildren, it’s really neat. You know, “if grandma can do it,” that kind of thing.
Nonpharmacologic is the first line of defense, of course, and we work with pharmaceutical companies, as well. It may be the best treatment would be a combination of a nonpharmacologic and a pharmacologic intervention together. Until we find a cure, I think maybe that would probably be the best combination. We should try to search for that. But right now, the nonpharmacologic interventions overwhelm. the pharmacologic interventions. So, we’ve got a ways to go.
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL
March 25th 2024The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).
Read More